stockrow
Friday 6 November 2026
Export AGL’s income statement to Excel — free account
Agilon Health, Inc.
AGL Healthcare Medical Care Facilities
Agilon Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.9 billion, down 2.11% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- +130.8%
- Free cash flow
- +234.4%
- Total debt
- −12.7%
Quarter to September 2026, against a year earlier
108.53
5.24
−4.61%
Follow AGL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.05 | 0.02 | 0.30 | 0.22 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.88) | 5.53 | (31.25) | 26.80 | |
P/B ratio |
2.25 | 0.72 | 7.87 | 4.76 | |
Price to Tangible BV |
4.67 | 1.10 | 10.70 | 6.05 | |
EV/Sales |
0.01 | (0.02) | 0.26 | 0.18 | |
EV/EBITDA |
0.00 | 0.35 | 0.00 | 0.00 | |
EV/Operating CF |
(0.33) | 2.83 | (21.64) | (249.26) | |
EV/FCF |
(0.23) | 1.66 | (14.75) | (27.74) | |
Quick Ratio |
0.89 | 0.95 | 1.00 | 1.08 | |
Current Ratio |
1.02 | 1.04 | 1.08 | 1.14 | |
Net Debt/EBITDA |
1.34 | (25.31) | (12.18) | (9.12) | |
Debt/Assets |
2.75% | 2.00% | 1.90% | 1.95% | |
Debt/Equity |
0.28 | 0.17 | 0.13 | 0.11 | |
Asset Turnover |
3.95 | 3.39 | 3.58 | 3.80 | |
Operating CF/Net income |
0.11 | 0.49 | (3.19) | 1.43 | |
Capex/Depreciation |
(1.40) | (0.46) | (0.63) | (0.48) | |
Interest Coverage |
(112.95) | 2.21 | 7.32 | 13.82 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
3.83% | 3.82% | 5.92% | 4.42% | |
Intangible Assets out of Total Assets |
0.05 | 0.04 | 0.04 | 0.00 | |
Share Based Compensation of Revenue |
0.61% | 0.44% | 1.59% | 1.24% | |
Graham Net Nets |
(0.17) | (0.02) | 0.03 | 0.09 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(137.92%) | (272.44%) | (13.28%) | (6.78%) | |
Free Cash Flow Yield |
(52.21%) | (65.04%) | (5.92%) | (2.85%) | |
Revenue per Share |
94.78 | 85.58 | 89.48 | 90.48 | |
Operating CF per Share |
(1.24) | 1.43 | (3.43) | 2.97 | |
Capex per Share |
(0.59) | (0.19) | (0.26) | (0.19) | |
Free Cash Flow per Share |
(1.83) | 1.24 | (3.69) | 2.78 | |
Cash per Share |
17.22 | 18.25 | 15.40 | 18.56 | |
Shareholders Equity per Share |
7.65 | 10.93 | 13.62 | 16.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.65 | 10.93 | 13.62 | 16.73 | |
Free Cash Flow |
(30.29) | 20.60 | (61.60) | 46.62 | |
Working Capital |
20.21 | 48.85 | 106.19 | 166.47 | |
Capital Expenditures |
(9.76) | (3.13) | (4.31) | (3.26) | |
Net Current Asset Value |
(47.86) | (2.33) | 54.73 | 115.15 | |
EV/EBIT |
0.00 | 0.32 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
845.42 | 1,069.67 | 1,053.48 | 982.14 | |
Average Payables |
173.91 | 214.59 | 223.41 | 235.74 | |
Average Assets |
1,502.64 | 1,718.90 | 1,652.12 | 1,580.88 | |
Average Common Equity |
298.84 | 340.84 | 318.23 | 293.48 |
Columns are period end dates · fundamentals updated 4 Nov 2026